Growth Hormone (HGH)

Research indicates that recombinant human growth hormone (rHGH) therapy has been studied extensively in adults with documented growth hormone deficiency, showing potential effects on body composition, bone density, and metabolic parameters. Clinical trials suggest that HGH replacement can increase lean body mass, reduce fat mass, and improve bone mineral density in deficient individuals. Studies have also investigated its effects on exercise capacity, quality of life measures, and cardiovascular risk factors, with mixed but generally positive results in appropriate patient populations.

The body of research includes numerous randomized controlled trials examining HGH in adults with pituitary disorders, childhood-onset growth hormone deficiency, and adult-onset deficiency. Studies suggest optimal dosing is individualized based on IGF-1 levels and clinical response, with most research focusing on doses ranging from 0.1-0.3 mg daily. However, research also indicates significant variability in individual responses and emphasizes the importance of proper patient selection and monitoring.

While studies demonstrate potential benefits in specific populations, research also highlights important safety considerations including potential effects on glucose metabolism, fluid retention, joint symptoms, and long-term cardiovascular outcomes. The evidence suggests HGH therapy requires careful medical supervision and regular monitoring of IGF-1 levels, glucose tolerance, and other metabolic parameters. Current research continues to refine optimal dosing protocols and identify patients most likely to benefit from treatment.